Mean VAS for pain and analgesic use scores at 2 weeks after initiation of treatment and the mean changes in scores compared with initial scores and scores 1 day after treatment in 18 patients treated by PV and 16 patients treated by OPM
| PV (n = 18) | OPM (n = 16) | Difference PV–OPM | 95% CI Difference | |
|---|---|---|---|---|
| Initial scores | ||||
| VAS for pain (range) | 7.1 (5–9) | 7.6 (5–10) | ||
| Analgesic use (range) | 1.9 (0–3) | 1.7 (0–3) | ||
| QUALEFFO (range) | 60 (37–86) | 67 (38–86) | ||
| RMD (range) | 15.7 (8–22) | 17.8 (9–24) | ||
| Scores after 2 weeks | ||||
| VAS for pain (range) | 4.9 (0–10) | 6.4 (3–9) | −1.5 | −3.2–0.2 |
| Change vs initial score | −2.1 | −1.1 | −1.0 | −0.5–2.5 |
| Change vs 1 day | +0.2 | −0.6 | 0.8 | −2.4–0.7 |
| Analgesic use | 1.2 (0–3) | 2.6 (2–3) | −1.4 | −2.0–−0.8 |
| Change vs initial score | −0.7 | +0.9 | −1.5 | −2.3–−0.8 |
| Change vs 1 day | −0.2 | −0.1 | −0.1 | −0.4–0.5 |
| QUALEFFO (range) | 53 (28–79) | 67 (40–88) | −14 | −24.7–−3.4 |
| Change | −6.8 | −0.7 | −6.1 | −10.7–−1.6 |
| RMD (range) | 13 (3–22) | 18 (9–23) | −5 | −8.4–−1.2 |
| Change (%) | +19 | −2 | 21 | 0.07–0.35 |
Note:—VAS indicates visual analog scale; PV, percutaneous vertebroplasty; OPM, optimal pain medication; CI, confidence interval; QUALEFFO, Quality of Life Questionnaire of the European Foundation for Osteoporosis; RMD, Roland-Morris Disability questionnaire.